AU4589289A - Synthetic antigens, a process for the preparation thereof and the use thereof - Google Patents

Synthetic antigens, a process for the preparation thereof and the use thereof

Info

Publication number
AU4589289A
AU4589289A AU45892/89A AU4589289A AU4589289A AU 4589289 A AU4589289 A AU 4589289A AU 45892/89 A AU45892/89 A AU 45892/89A AU 4589289 A AU4589289 A AU 4589289A AU 4589289 A AU4589289 A AU 4589289A
Authority
AU
Australia
Prior art keywords
preparation
synthetic antigens
antigens
synthetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU45892/89A
Inventor
Klaus-Dieter Hungerer
Hermann Pelzer
Werner Stuber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics GmbH Germany
Original Assignee
Behringwerke AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke AG filed Critical Behringwerke AG
Publication of AU4589289A publication Critical patent/AU4589289A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/06—Peptides being immobilised on, or in, an organic carrier attached to the carrier via a bridging agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU45892/89A 1988-12-07 1989-12-06 Synthetic antigens, a process for the preparation thereof and the use thereof Abandoned AU4589289A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3841091A DE3841091A1 (en) 1988-12-07 1988-12-07 SYNTHETIC ANTIGENS, METHOD FOR THEIR PRODUCTION AND THEIR USE
DE3841091 1988-12-07

Publications (1)

Publication Number Publication Date
AU4589289A true AU4589289A (en) 1990-06-14

Family

ID=6368560

Family Applications (1)

Application Number Title Priority Date Filing Date
AU45892/89A Abandoned AU4589289A (en) 1988-12-07 1989-12-06 Synthetic antigens, a process for the preparation thereof and the use thereof

Country Status (8)

Country Link
EP (1) EP0372501A3 (en)
JP (1) JPH02223599A (en)
KR (1) KR900009095A (en)
AU (1) AU4589289A (en)
CA (1) CA2004810A1 (en)
DE (1) DE3841091A1 (en)
DK (1) DK614289A (en)
PT (1) PT92499A (en)

Families Citing this family (180)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7118757B1 (en) 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
EP0467714A1 (en) * 1990-07-19 1992-01-22 Merck & Co. Inc. The class II protein of the outer membrane of neisseria meningitidis
EP0519554A1 (en) * 1991-06-19 1992-12-23 Merck & Co. Inc. Conjugates of the class II protein of the outer membrane of neisseria meningitidis and of HIV-1 related peptides
ATE355375T1 (en) 1996-01-04 2006-03-15 Novartis Vaccines & Diagnostic BACTERIOFERRITIN FROM HELICOBACTER PYLORI
NZ593617A (en) 2000-10-27 2012-04-27 Novartis Vaccines & Diagnostic Nucleic acids and proteins from streptococcus groups A & B
US7082569B2 (en) 2001-01-17 2006-07-25 Outlooksoft Corporation Systems and methods providing dynamic spreadsheet functionality
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
CN100515494C (en) 2001-12-12 2009-07-22 启龙有限公司 Immunisation against chlamydia trachomatis
CA2476626A1 (en) 2002-02-20 2003-08-28 Chiron Corporation Microparticles with adsorbed polypeptide-containing molecules
MXPA04011249A (en) 2002-05-14 2005-06-06 Chiron Srl Mucosal vaccines with chitosan adjuvant and meningococcal antigens.
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
EP1549338B1 (en) 2002-10-11 2010-12-22 Novartis Vaccines and Diagnostics S.r.l. Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
EP2279746B1 (en) 2002-11-15 2013-10-02 Novartis Vaccines and Diagnostics S.r.l. Surface proteins in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
AU2003299994A1 (en) 2002-12-27 2004-07-29 Chiron Corporation Immunogenic compositions containing phospholpid
WO2004067030A2 (en) 2003-01-30 2004-08-12 Chiron Srl Injectable vaccines against multiple meningococcal serogroups
EP1608369B1 (en) 2003-03-28 2013-06-26 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
US9107831B2 (en) 2003-06-02 2015-08-18 Novartis Vaccines And Diagonstics, Inc. Immunogenic compositions containing microparticles comprising adsorbed toxoid and polysaccharide-containing antigens
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
US8765135B2 (en) 2003-10-02 2014-07-01 Novartis Ag Liquid vaccines for multiple meningococcal serogroups
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0408978D0 (en) 2004-04-22 2004-05-26 Chiron Srl Meningococcal fermentation for preparing conjugate vaccines
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
EP2583678A3 (en) 2004-06-24 2013-11-13 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
EP2277595A3 (en) 2004-06-24 2011-09-28 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
US20060165716A1 (en) 2004-07-29 2006-07-27 Telford John L Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
GB0502096D0 (en) 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
WO2006091517A2 (en) 2005-02-18 2006-08-31 Novartis Vaccines And Diagnostics Inc. Immunogens from uropathogenic escherichia coli
PL2351772T3 (en) 2005-02-18 2017-01-31 Glaxosmithkline Biologicals Sa Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli
EP2329843A3 (en) 2005-04-18 2011-09-14 Novartis Vaccines and Diagnostics, Inc. Expressing Hepatitis B Virus surface antigen for vaccine preparation
ES2750243T3 (en) 2005-06-27 2020-03-25 Glaxosmithkline Biologicals Sa Vaccine composition comprising conjugated natural capsular polysaccharides from N. Meningitidis
ES2443529T3 (en) 2005-09-01 2014-02-19 Novartis Vaccines And Diagnostics Gmbh Multiple vaccination including serogroup C meningococcus
GB0522303D0 (en) 2005-11-01 2005-12-07 Chiron Srl Culture method
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
CA2630220C (en) 2005-11-22 2020-10-13 Doris Coit Norovirus and sapovirus antigens
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
CN110179974B (en) 2005-12-22 2024-01-09 葛兰素史密丝克莱恩生物有限公司 Vaccine
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
EP2357001B1 (en) 2006-03-22 2018-03-07 GlaxoSmithKline Biologicals S.A. Regimens for immunisation with meningococcal conjugates
ATE539079T1 (en) 2006-03-23 2012-01-15 Novartis Ag IMIDAZOCHINOXALINE COMPOUNDS AS IMMUNE MODULATORS
EP2054431B1 (en) 2006-06-09 2011-08-31 Novartis AG Conformers of bacterial adhesins
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
AU2007285484B2 (en) 2006-08-16 2013-05-02 Novartis Ag Immunogens from uropathogenic Escherichia coli
DK2066344T3 (en) 2006-09-07 2011-09-05 Glaxosmithkline Biolog Sa Inactivated Poliovirus combination vaccine
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
MX2009011837A (en) 2007-05-02 2010-04-22 Glaxosmithkline Biolog Sa Vaccine.
CN104873965B (en) 2007-06-26 2018-09-11 葛兰素史密丝克莱恩生物有限公司 Include the vaccine of streptococcus pneumoniae capsular polysaccharide conjugates
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
ES2561483T3 (en) 2007-09-12 2016-02-26 Glaxosmithkline Biologicals Sa GAS57 mutant antigens and GAS57 antibodies
CA2702871A1 (en) 2007-10-19 2009-04-23 Novartis Ag Meningococcal vaccine formulations
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
CN101977926B (en) 2007-12-21 2014-10-08 诺华股份有限公司 Mutant forms of streptolysin O
BRPI0907843A2 (en) 2008-02-21 2015-08-04 Novartis Ag Menigococcal fhbp polypeptides
PT2349520T (en) 2008-10-27 2016-08-16 Glaxosmithkline Biologicals Sa Purification method for carbohydrate from group a streptococcus
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
BRPI0923006A2 (en) 2008-12-17 2016-03-08 Novartis Ag meningococcal vaccines including hemoglobin receptor
CN105056229A (en) 2009-01-05 2015-11-18 埃皮托吉尼西斯股份有限公司 Adjuvant compositions and methods of use
EP2385842A1 (en) 2009-01-12 2011-11-16 Novartis AG Cna_b domain antigens in vaccines against gram positive bacteria
EP3263128A3 (en) 2009-04-14 2018-01-24 GlaxoSmithKline Biologicals S.A. Compositions for immunising against staphylococcus aureus
RU2536248C2 (en) 2009-04-30 2014-12-20 Коули Фармасьютикал Груп, Инк. Pneumococcal vaccine and using it
US8668911B2 (en) 2009-05-14 2014-03-11 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
EP2470204B1 (en) 2009-08-27 2015-12-16 GlaxoSmithKline Biologicals SA Hybrid polypeptides including meningococcal fhbp sequences
SI2473605T1 (en) 2009-09-03 2018-06-29 Pfizer Vaccines Llc Pcsk9 vaccine
EP2475385A1 (en) 2009-09-10 2012-07-18 Novartis AG Combination vaccines against respiratory tract diseases
CA2779798C (en) 2009-09-30 2019-03-19 Novartis Ag Conjugation of staphylococcus aureus type 5 and type 8 capsular polysaccharides
WO2011039631A2 (en) 2009-09-30 2011-04-07 Novartis Ag Expression of meningococcal fhbp polypeptides
AU2010310985B2 (en) 2009-10-27 2014-11-06 Glaxosmithkline Biologicals S.A. Modified meningococcal fHBP polypeptides
AU2010310919B2 (en) 2009-10-30 2015-05-07 Glaxosmithkline Biologicals S.A. Purification of Staphylococcus aureus type 5 and type 8 capsular saccharides
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
WO2011149564A1 (en) 2010-05-28 2011-12-01 Tetris Online, Inc. Interactive hybrid asynchronous computer game infrastructure
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
EP2655389A2 (en) 2010-12-24 2013-10-30 Novartis AG Compounds
US10286056B2 (en) 2011-01-27 2019-05-14 Glaxosmithkline Biologicals S.A. Adjuvant nanoemulsions with crystallisation inhibitors
EP2680883B1 (en) 2011-03-02 2018-09-05 Pfizer Inc Pcsk9 vaccine
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
ES2785108T3 (en) 2011-03-24 2020-10-05 Glaxosmithkline Biologicals Sa Adjuvant nanoemulsions with phospholipids
EP2511295A1 (en) 2011-04-15 2012-10-17 Institut National De La Sante Et De La Recherche Medicale Compositions for preventing and/or treating an infection by an HIV-1 virus
EP2723378A4 (en) 2011-06-24 2015-01-28 Epitogenesis Inc Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators
WO2013009564A1 (en) 2011-07-08 2013-01-17 Novartis Ag Tyrosine ligation process
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
US9358284B2 (en) 2011-09-14 2016-06-07 Glaxosmithkline Biologicals Sa Methods for making saccharide-protein glycoconjugates
MX354924B (en) 2011-11-07 2018-03-22 Novartis Ag Carrier molecule comprising a spr0096 and a spr2021 antigen.
EP2592137A1 (en) 2011-11-11 2013-05-15 Novartis AG Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
DE102011118371B4 (en) 2011-11-11 2014-02-13 Novartis Ag Composition suitable for human vaccination, comprising a diphtheria toxoid, and process for its preparation
DE102011122891B4 (en) 2011-11-11 2014-12-24 Novartis Ag Fermentation medium, which is free of animal components, for the preparation of diphtheria toxoids for use in the vaccination of humans
MX2014006630A (en) 2011-12-08 2014-07-09 Novartis Ag Clostridium difficile toxin-based vaccine.
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
RU2014138418A (en) 2012-02-24 2016-04-10 Новартис Аг PROTEINS OF SAWS AND COMPOSITIONS
CN104519910B (en) 2012-03-07 2017-05-03 诺华股份有限公司 Adjuvanted formulations of streptococcus pneumoniae antigens
SA115360586B1 (en) 2012-03-09 2017-04-12 فايزر انك Neisseria meningitidis compositions and methods thereof
KR102139959B1 (en) 2012-04-26 2020-08-04 노파르티스 아게 Antigens and antigen combinations
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
SG11201407440WA (en) 2012-05-22 2014-12-30 Novartis Ag Meningococcus serogroup x conjugate
JP6266631B2 (en) 2012-10-03 2018-01-24 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Immunogenic composition
SG11201502599TA (en) 2012-10-12 2015-05-28 Glaxosmithkline Biolog Sa Non-cross-linked acellular pertussis antigens for use in combination vaccines
EP3345617B1 (en) 2012-11-30 2020-08-26 GlaxoSmithKline Biologicals S.A. Pseudomonas antigens and antigen combinations
TR201807340T4 (en) 2013-02-01 2018-06-21 Glaxosmithkline Biologicals Sa Intradermal administration of immunological compositions comprising bell-like receptor agonists.
KR101905278B1 (en) 2013-09-08 2018-10-08 화이자 인코포레이티드 Neisseria meningitidis compositions and methods thereof
PL3096783T3 (en) 2014-01-21 2021-12-13 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
KR102157200B1 (en) 2014-01-21 2020-09-21 화이자 인코포레이티드 Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
IL311385A (en) 2014-01-21 2024-05-01 Pfizer Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
ES2701169T3 (en) 2014-02-14 2019-02-21 Pfizer Immunogenic glycoprotein conjugates
HUE052293T2 (en) 2014-02-28 2021-04-28 Glaxosmithkline Biologicals Sa Modified meningococcal fhbp polypeptides
EP3034516A1 (en) 2014-12-19 2016-06-22 Novartis AG Purification of streptococcal capsular polysaccharide
FI3244917T3 (en) 2015-01-15 2023-05-25 Pfizer Immunogenic compositions for use in pneumococcal vaccines
WO2016184962A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
WO2016184963A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
EP3109255A1 (en) 2015-06-26 2016-12-28 Institut National De La Recherche Agronomique Immunogenic composition
BR112018000087A2 (en) 2015-07-21 2018-09-04 Pfizer Inc. immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising them and uses thereof
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
JP6884145B2 (en) 2015-11-20 2021-06-09 ファイザー・インク Immunogenic composition for use in Streptococcus pneumoniae vaccine
JP7099956B2 (en) 2015-12-04 2022-07-12 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Vaccination with MICA / B alpha 3 domain for the treatment of cancer
WO2017175082A1 (en) 2016-04-05 2017-10-12 Gsk Vaccines S.R.L. Immunogenic compositions
EP3506933A2 (en) 2016-09-02 2019-07-10 GlaxoSmithKline Biologicals SA Vaccines for neisseria gonorrhoeae
IL296165B2 (en) 2016-10-07 2023-10-01 Enterome S A Immunogenic compounds for cancer therapy
US11478538B2 (en) 2016-10-07 2022-10-25 Enterome S.A. Immunogenic compounds for cancer therapy
EP3551668A1 (en) 2016-12-06 2019-10-16 GlaxoSmithKline Biologicals S.A. Purification process for capsular polysaccharide
SI3570879T1 (en) 2017-01-20 2022-06-30 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
CA3051801A1 (en) 2017-01-31 2018-08-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN112118863A (en) 2018-04-11 2020-12-22 恩特罗姆公司 Antigenic peptides for the prevention and treatment of cancer
EP3773673A2 (en) 2018-04-11 2021-02-17 Enterome S.A. Immunogenic compounds for treatment of fibrosis, autoimmune diseases and inflammation
JP7446279B2 (en) 2018-07-19 2024-03-08 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Method for preparing dry polysaccharide
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
CA3120922A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
WO2020165711A1 (en) 2019-02-11 2020-08-20 Pfizer Inc. Neisseria meningitidiscompositions and methods thereof
JP7239509B6 (en) 2019-02-22 2023-03-28 ファイザー・インク Method for purifying bacterial polysaccharides
US20220184199A1 (en) 2019-04-10 2022-06-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
US20220211859A1 (en) 2019-05-10 2022-07-07 Glaxosmithkline Biologicals Sa Conjugate production
WO2021021729A1 (en) 2019-07-31 2021-02-04 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
BR112022004921A2 (en) 2019-09-27 2022-07-19 Pfizer COMPOSITIONS FOR NEISSERIA MENINGITIDIS AND METHODS THEREOF
US20230105457A1 (en) 2019-10-16 2023-04-06 Enterome S.A. Immunogenic Compounds For Treatment Of Adrenal Cancer
EP4051696A1 (en) 2019-11-01 2022-09-07 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2021094562A2 (en) 2019-11-15 2021-05-20 Enterome S.A. Antigenic peptides for prevention and treatment of b-cell malignancy
CN114728051A (en) 2019-11-22 2022-07-08 葛兰素史克生物有限公司 Dosage and administration of bacterial glycoconjugate vaccines
AU2021224078B2 (en) 2020-02-21 2024-01-18 Pfizer Inc. Purification of saccharides
CA3173729A1 (en) 2020-02-23 2021-08-26 Pfizer Inc. Escherichia coli compositions and methods thereof
EP4165064A2 (en) 2020-06-12 2023-04-19 GlaxoSmithKline Biologicals S.A. Dock tag system
GB202013262D0 (en) 2020-08-25 2020-10-07 Glaxosmithkline Biologicals Sa Vaccine Composition
EP4232593A1 (en) 2020-10-22 2023-08-30 Pfizer Inc. Methods for purifying bacterial polysaccharides
EP4237428A2 (en) 2020-10-27 2023-09-06 Pfizer Inc. Escherichia coli compositions and methods thereof
KR20230097160A (en) 2020-11-04 2023-06-30 화이자 인코포레이티드 Immunogenic compositions for use in pneumococcal vaccines
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
EP4070814A1 (en) 2021-04-07 2022-10-12 Lama France Sars-cov-2 polypeptides and uses thereof
CA3218544A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against bacterial and betacoronavirus infections
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
EP4346893A2 (en) 2021-05-28 2024-04-10 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
JP2024522395A (en) 2021-05-28 2024-06-19 ファイザー・インク Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
IL314243A (en) 2022-01-13 2024-09-01 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
AU2023246941A1 (en) 2022-03-31 2024-10-24 Enterome S.A. Antigenic peptides for prevention and treatment of cancer.
AU2023268745A1 (en) 2022-05-11 2024-11-07 Pfizer Inc. Process for producing of vaccine formulations with preservatives
GB202208089D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202208093D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
WO2024110839A2 (en) 2022-11-22 2024-05-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024116096A1 (en) 2022-12-01 2024-06-06 Pfizer Inc. Pneumococcal conjugate vaccine formulations
WO2024166008A1 (en) 2023-02-10 2024-08-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024201324A2 (en) 2023-03-30 2024-10-03 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024214016A1 (en) 2023-04-14 2024-10-17 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1329124C (en) * 1987-02-02 1994-05-03 Jerald C. Sadoff Conjugate malaria vaccine

Also Published As

Publication number Publication date
DE3841091A1 (en) 1990-06-13
EP0372501A2 (en) 1990-06-13
KR900009095A (en) 1990-07-02
PT92499A (en) 1990-06-29
DK614289D0 (en) 1989-12-06
DK614289A (en) 1990-06-08
CA2004810A1 (en) 1990-06-07
JPH02223599A (en) 1990-09-05
EP0372501A3 (en) 1990-10-10

Similar Documents

Publication Publication Date Title
AU4589289A (en) Synthetic antigens, a process for the preparation thereof and the use thereof
AU2732288A (en) Polyethylene wax, and a process for the preparation thereof
AU4965185A (en) A surface coated article, process and means for the preparation thereof and use thereof
AU3273989A (en) Ceramic foam and a process for forming the same
AU623766B2 (en) N-heteroaryl-4-quinolinamines, a process for their preparation and their use as medicaments
AU624436B2 (en) Albumin preparation and process for preparing the same
AU4733389A (en) Bisindenyl derivatives, and a process for the preparation thereof
AU7465887A (en) A fiber-containing product, a process for the preparation thereof, and the use thereof
AU2653788A (en) Manumycin derivatives, a process for the preparation thereof, and the use thereof
AU1446688A (en) New 2-acylpyrrolidine derivatives, a process for the preparation thereof, agents containing them, and their use
AU4935390A (en) A novel substituted-acetamide compound and a process for the preparation thereof
AU7285087A (en) Matrix material, a process for the preparation thereof, and its use
AU6843190A (en) A thermoplastic polyurethane and a process for the preparation thereof
AU2295988A (en) Renin-inhibiting dipeptides, a process for the preparation thereof, agents containing them, and their use
AU633073B2 (en) Stabilized synthetic zeolite and a process for the preparation thereof
AU5717990A (en) Magnetic protein conjugates, a process for the preparation thereof and the use thereof
AU2975089A (en) Novel compounds, process for the preparation thereof and uses thereof
AU609980B2 (en) Hydrazinocarbonyloxylabdanes, a process for their preparation and their use as medicaments
GB8918807D0 (en) A solid pesticidal formulation,a process for its preparation and the use thereof
AU6255690A (en) Opaliform porcellanite and process for the preparation thereof
ZA894381B (en) Substituted 3-aminosydnone imines,a process for their preparation and their use
GB2199827B (en) Novel aminoalkanoyl-dibenzo[d,g][1,3,6]dioxazocines and a process for the preparation thereof
AU6689590A (en) Pyridine-2,4- and 2,5-dicarboxamides, a process for the preparation thereof, and the use thereof
AU3244589A (en) Sakyomicine and acyclated derivatives thereof, a process for the preparation thereof and the use thereof
AU3698789A (en) Antibodies